GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

GSK Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

GSK plcNYSE: GSK

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin narrows to 5.2%

Net margin was 5.2% in Q2 FY2026, down 12.9 pp from a year earlier. On a trailing-twelve-month basis it was 14.5%, up 3.7 pp year over year. Over 3 fiscal years it narrowed by 33.5 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 16 analysts of 21.9% for the fiscal year ending Dec 2026, up from 17.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
5.2%-17.6 pp QoQ
Last fiscal yearDec 2025
17.5%+9.3 pp YoY
LTMJun 2026
14.5%+3.7 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-12.9 pp-0.5 pp+12.4 pp
1 year+9.3 pp+4.4 pp-4.9 pp
3 years-33.5 pp+5.1 pp+38.6 pp
5 years+6.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
17.5%
Year-over-year change
+9.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How GSK compares with its peers on the latest reported figures

  • GSK's LTM Jun 2026 net margin of 14.5% is the 7th highest of the 10 companies compared; the peer median is 17.7%.
  • Its year-over-year change of +3.7 pp is the 3rd highest of 10, against a peer median of -1.8 pp.
  • Over three fiscal years its change of -33.5 pp compares with a peer median of +3.6 pp.
GSK Competitors Peer median
Net Margin for GSK and competitors
Company Period LTM level YoY 3-year change
NVONovo Nordisk A/SLTM Jun 202635.3% -0.3 pp+1.8 pp
LLYEli Lilly and CompanyLTM Jun 202633.5% +7.6 pp+9.8 pp
NVSNovartis AGLTM Jun 202622.9% -1.8 pp+9.6 pp
AMGNAmgen Inc.LTM Jun 202622.9% +4.0 pp-3.9 pp
AZNAstraZeneca PLCLTM Sep 202617.7% +1.5 pp+10.0 pp
JNJJohnson & JohnsonLTM Sep 202616.2% -11.1 pp+6.0 pp
GSKGSK plcLTM Jun 202614.5% +3.7 pp-33.5 pp
SNYSanofiLTM Jun 20268.1% -13.1 pp-3.9 pp
PFEPfizer Inc.LTM Jun 20266.8% -10.0 pp-18.6 pp
MRKMerck & Co., Inc.LTM Jun 20264.8% -21.0 pp+3.6 pp
Peer median (excluding GSK) 17.7%-1.8 pp+3.6 pp

Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue24.7B29.32B30.33B31.38B32.67B
Cost of Revenue8.16B9.55B8.57B9.05B9.02B
Gross Profit16.53B19.77B21.76B22.33B23.65B
Gross Margin66.9%67.4%71.8%71.2%72.4%
Research & Development5.02B5.49B6.22B6.4B7.53B
Selling, General & Admin7.07B8.37B9.39B11.02B9.09B
Operating Expenses12.18B13.34B15.02B18.31B15.31B
Depreciation & Amortization2.12B2.15B2.29B2.55B2.31B
EBITDA6.49B8.6B9.08B6.67B10.4B
EBITDA Margin26.3%29.3%29.9%21.3%31.8%
Operating Income4.36B6.43B6.75B4.02B8.34B
Operating Margin17.6%21.9%22.2%12.8%25.5%
Interest Income28M64.27M40M67.39M56M
Interest Expense784M855.53M775M657.58M687M
Other Income / Expenses(758M)(805M)(681M)(544M)(937M)
Income Before Tax3.6B5.63B6.06B3.48B7.4B
Pre-Tax Margin14.6%19.2%20.0%11.1%22.7%
Income Tax Expense83M707M756M526M1.11B
Net Income4.39B14.96B4.93B2.58B5.72B
Net Margin17.8%51.0%16.2%8.2%17.5%
EPS (Basic)2.747.442.441.262.82
EPS (Diluted)2.707.322.401.242.78
Weighted Avg Shares1.6B2.01B2.03B2.04B2.03B
Weighted Avg Shares (Diluted)1.62B2.04B2.06B2.07B2.06B

GSK plc

NYSE:GSK

Intrinsic Alpha fair value

Locked

Current Price

$48.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.